X

Trial Profile

A phase Ib study assessing cohort expansion study of ARV-471 in combination with Ibrance

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 11 Aug 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Palbociclib (Primary) ; Vepdegestrant (Primary)
Indications Advanced breast cancer
Focus Adverse reactions
Sponsors Arvinas

Most Recent Events

04 Aug 2022 According to an Arvinas media release, the company plans to present safety data from the Phase 1b combination trial with palbociclib at a medical conference in 1H 2023
28 Feb 2022 According to an Arvinas media release, safety data from the Phase 1b combination trial with palbociclib is expected in 2H 2022.
14 Dec 2020 According to an Arvinas media release, this study is expected to begin in December 2020.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com